Industrialising Tissue Engineering – The Technology at the Heart of BSF Enterprise

In this interview, Dr. Che Connon, CEO of BSF Enterprise, explains how the acquisition of 3D Bio-Tissues from Newcastle University has positioned BSF at the forefront of industrialised tissue engineering.

Dr. Connon outlines how 3D Bio-Tissues serves as BSF’s core technology engine - generating proprietary IP that is licensed into subsidiaries to drive focused commercial growth across multiple applications, including cultivated leather, corneal repair, and advanced cell media supplements.

The discussion highlights recent commercial progress within the Group, particularly:

• City-Mix™, a powdered media supplement sold to cultivated meat companies

• CytoBoost™, a formulated supplement for biopharma and research facilities

• CytoBoost Revive, a newly launched, class-leading supplement designed to enhance post-thaw cell recovery

Dr. Connon also explains why tissue engineering represents the next logical step in the commercial evolution of biology - moving from genes, to proteins, to cells, and now to functional tissues. BSF has demonstrated that groups of cells can be industrialised into complex tissues, unlocking scalable and commercially viable biological materials.

The interview also explores the strategic opportunity in lab-grown leather, including:

• Cruelty-free production aligned with changing consumer values

• Reduced water usage and sustainability advantages

• Greater manufacturing consistency

• The ability to create material properties impossible to achieve with animal-derived leather

This video provides investors with insight into BSF’s long-term strategy: combining synthetic biology and tissue engineering to create sophisticated, high-performance biological materials and building independent, high-growth subsidiaries powered by proprietary IP.